Paxlovid, Molnupiravir, Sotrovimab Appear Cost Effective To ICER; But Data, Price Could Change
With the US government currently negotiating prices and drugs mostly going to high-risk patients, ICER’s draft ‘special assessment’ of COVID treatments offers an approach to adapting research on safety and effectiveness in order to provide guidance to clinicians, payers and other stakeholders.
You may also be interested in...
Group’s final report said evidence was inadequate to demonstrate a net health benefit versus symptomatic care for Lagevrio, a drug that has already taken a back seat to Pfizer’s Paxlovid.
Drug developers discuss transitioning the pricing and purchasing of their COVID treatments to the private market during an advisory panel meeting hosted by the Institute for Clinical and Economic Review.
US government is paying Merck & Co. around $181 more per course of treatment for its oral antiviral for COVID-19, molnupiravir, than it is to Pfizer for its competing drug.